Floatz logo

Gilteritinib

Relapsed Adult AML

French Innovative Leukemia OrganisationSmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
89/ 100

Competitive context

13 Active assets in the Relapsed Adult AML cohort.

Asset / SponsorPhaseRating
Azacitidine
Institute of Hematology & Blood Diseases Hospital, China
Phase 2B
Venetoclax
Medical College of Wisconsin
Phase 2B
FILGRASTIM
Medical College of Wisconsin
Phase 2B
Cytosin-Arabinosid
Medical College of Wisconsin
Phase 2B
Tucidinostat
The First Affiliated Hospital of Xiamen University
Phase 2CCC

View all 19 →

Same molecule, other indications

Gilteritinib is also rated in:

acute myeloid leukemia, FLT3 internal tandem duplicationDormant
BB
Indicative ·
69 / 100
View asset →
myelodysplastic syndrome with excess blasts-2Dormant
BB
Indicative ·
66 / 100
View asset →
acute myeloid leukemiaDormant
BB
Indicative ·
65 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →